Review of Industry Documents Regarding
Dissolvable Tobacco Products: Behavioral Effects

Jeanette Renaud, Ph.D.
Elvira Elek, Ph.D.
Betty Brown, M.P.H.
RTI International

Presented to:
Tobacco Product Scientific Advisory Committee
Food and Drug Administration
Rockville, MD
January 2012

RTI International is a trade name of Research Triangle Institute.
Purpose

- RTI International identified, reviewed, and summarized industry documents related to behavioral effects of dissolvable tobacco products
- Inform recommendations of the Tobacco Product Scientific Advisory Committee (TPSAC) regarding the use and impact of dissolvable tobacco products on public health
- **Disclaimer:** Although the work reported was done under contract with Center for Tobacco Products at FDA, the content and conclusions of this presentation are those of RTI International.
Topic

- **Behavioral Effects** of Dissolvable Tobacco Products

- Looked for information regarding:
  - Initiation
  - Dual use
  - Switching
  - Cessation
Approach

- Three reviewers examined 287 documents submitted to FDA-CTP by 8 tobacco companies
- 63 documents were self-identified as including information relevant to behavioral effects
- 224 potentially relevant documents were identified via additional keyword searches, using the following search terms:
  - Initiate/Initiation
  - Dual Use
  - Switch/Switched/Switcher/Switching or Migrate/Migration
  - Cessation or Quit or Abstain/Abstinence
Commerical Confidential Information

- Data reported in the open meeting are limited to information deemed not commercial confidential. The commercial confidential information will be presented to TPSAC SGEs in closed session
Limitations

- Many documents are proposals, protocols, IRB approvals, etc, and therefore, do not include findings

- Short-term clinical trials for test products/concepts